
ABSTRACT

There is provided a CRF receptor antagonist comprising a compound of the formula (I):

$$A-W-Ar$$
 (I)

wherein, A is a group represented by the formula (A1) or (A2):



(wherein, ring Aa is a 5- or 6- membered ring which may be further substituted; ring Ab is a 5- or 6- membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R¹ is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X is carbonyl, -O-, -S-, etc.; Y¹, Y² and Q are independently optionally substituted carbon or nitrogen; ··· is a single or double bond);

W is a bond, optionally substituted methylene, optionally substituted imino, -O-, -S-, etc.; Ar is optionally substituted aryl or optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.

10

15